MEK-ERK信号通路是转移性去势抵抗性前列腺癌的治疗靶点
研究比较101例转移性去势抵抗性前列腺癌(mCRPC)患者转移灶mRNA表达与TCGA局限于前列腺癌组织的mRNA表达,推断激酶活性差异,发现ERK1过度活化及MAPK通路成员扩增。原发肿瘤中可检测到磷酸化ERK1/2与根治性前列腺切除术后生化失败相关。曲美替尼在一例多线治疗失败的mCRPC患者中引发深刻生化和临床反应。作者结论为药理学靶向MEK/ERK通路可能是难治性转移性前列腺癌的可行治疗策略,一项II期试验正在进行。
要点
- mCRPC转移灶转录组分析提示ERK1过度活化,32%队列存在MAPK通路成员扩增。
- 原发肿瘤可检测到磷酸化ERK1/2与根治性前列腺切除术后生化失败相关,独立于临床病理特征。
- 曲美替尼在一例多线治疗失败的mCRPC患者中引发深刻生化和临床反应。
核心结论
- 药理学靶向MEK/ERK通路可能是难治性转移性前列腺癌的可行治疗策略。
- 一项正在进行的II期试验检验该假设。
研究设计与样本
- 比较101例mCRPC患者转移活检mRNA表达与TCGA局限于前列腺癌的mRNA表达,推断差异激酶活性。
- 评估mCRPC与局限于前列腺癌之间关键MAPK通路激酶的差异磷酸化水平。
- 全基因组测序分析MAPK通路成员扩增。
- 在一例多线治疗失败的mCRPC患者中观察曲美替尼的生化与临床反应。
主要发现
- 101例mCRPC患者转录组分析对比局限于前列腺癌患者,发现ERK1过度活化的证据。
- 全基因组测序显示该队列32%存在MAPK通路成员频繁扩增。
- 去势抵抗性前列腺癌中磷酸化ERK1/2水平高于未经治疗的原发性前列腺癌。
- 原发肿瘤中可检测到磷酸化ERK1/2与根治性前列腺切除术后生化失败相关,独立于临床病理特征。
- 曲美替尼在一例多线治疗失败的mCRPC患者中引发深刻生化和临床反应。
关键数值与推荐
- ERK1是MEK1/2的直接下游靶点,MEK1/2可被曲美替尼(已批准用于黑色素瘤的治疗药物)靶向。
- 全基因组测序显示32%的mCRPC队列存在MAPK通路成员扩增。
临床怎么用
- 作者认为药理学靶向MEK/ERK通路可能是难治性转移性前列腺癌的可行治疗策略。
- 一项正在进行的II期试验检验该假设。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic castration resistant prostate cancer (mCRPC) is incurable and progression after drugs that target the androgen receptor-signaling axis is inevitable. Thus, there is an urgent need to develop more effective treatments beyond hormonal manipulation. We sought to identify activated kinases in mCRPC as therapeutic targets for existing, approved agents, with the goal of identifying candidate drugs for rapid translation into proof of concept Phase II trials in mCRPC. METHODS: To identify evidence of activation of druggable kinases in these patients, we compared mRNA expression from metastatic biopsies of patients with mCRPC (n = 101) to mRNA expression in localized prostate from TCGA and used this analysis to infer differential kinase activity. In addition, we assessed the differential phosphorylation levels for key MAPK pathway kinases between mCRPC and localized prostate cancers. RESULTS: Transcriptomic profiling of 101 patients with mCRPC as compared to patients with localized prostate cancer identified evidence of hyperactive ERK1, and whole genome sequencing revealed frequent amplifications of members of the MAPK pathway in 32% of this cohort. Next, we confirmed elevated levels of phosphorylated ERK1/2 in castration resistant prostate cancer as compared to untreated primary prostate cancer. We observed that the presence of detectable phosphorylated ERK1/2 in the primary tumor is associated with biochemical failure after radical prostatectomy independent of clinicopathologic features. ERK1 is the immediate downstream target of MEK1/2, which is druggable with trametinib, an approved therapeutic for melanoma. Trametinib elicited a profound biochemical and clinical response in a patient who had failed multiple prior treatments for mCRPC. CONCLUSIONS: We conclude that pharmacologic targeting of the MEK/ERK pathway may be a viable treatment strategy for patients with refractory metastatic prostate cancer. An ongoing Phase II trial tests this hypothesis.
引用
- Nickols NG, Nazarian R, Zhao SG, et al. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019. PMID: 30804427. doi:10.1038/s41391-019-0134-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。